CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Patrick Gray to the Dicerna board of directors (the “board”) as an independent director, and the retirement of veteran director Dennis Langer, M.D., J.D. Mr. Gray will serve as the chairperson of the Audit Committee. Mr. Gray’s appointment is effective immediately.
“As Dicerna continues to grow and mature, our board continues to evolve with the addition of Patrick Gray. Patrick is an accomplished CPA, executive, and director who brings with him extensive industry experience that will help further advance our GalXC-based pipeline and strengthen Dicerna’s position in the promising field of RNAi therapeutics,” said Douglas M. Fambrough, Ph.D., president and chief executive officer of Dicerna. “We sincerely thank Dennis Langer, who has been on our board since 2007, for his meaningful and numerous contributions over the years. Dennis has played a key role in the growth of our company with his strategic insights, sage counsel, and guidance.”
Mr. Gray currently serves as a member of the board and as chairperson of the audit committee of Tmunity Therapeutics, Inc. He previously served as a member of the board and as the chairperson of the audit committee of Civitas Solutions, Inc., from September 2014 to March 2019, Sancilio Pharmaceuticals Company, Inc., from February 2012 through August 2018, and Datto, Inc., from May 2015 through December 2017. Mr. Gray spent 37 years with PricewaterhouseCoopers LLP (“PwC”) until his retirement in 2009. He is a certified public accountant who spent 25 years as an Audit Partner at PwC. At the time of his retirement, he served as the lead partner for the PwC U.S. firm’s Corporate Governance Group. Prior to that time, Mr. Gray held various other leadership positions within the firm, including leadership of the PwC U.S. High Technology Group. Mr. Gray holds a B.S. in Economics from The Wharton School, University of Pennsylvania.
“I am pleased to join the Dicerna board of directors at such an important time for the company as it advances its promising pipeline and engages in strategic partnerships with leading pharmaceutical companies to further extend the potential of its technology,” commented Mr. Gray. “I look forward to helping Dicerna continue to execute on and achieve its goal of developing and delivering innovative and effective therapies for patients in need.”
About DicernaTM Pharmaceuticals, Inc.
Dicerna™ Pharmaceuticals, Inc. (“we”, “us,” “our,” “the Company,” or “Dicerna”) is a biopharmaceutical company using ribonucleic acid (RNA) interference (RNAi) to develop medicines that silence genes that cause disease. The Company’s proprietary GalXC™ technology is being applied to develop potent, selective, and safe RNAi therapies to treat diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna aims to treat disease by addressing the underlying causes of illness with capabilities that extend beyond the liver to address a broad range of diseases, focusing on target genes where connections between gene and disease are well understood and documented. Dicerna intends to discover, develop, and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company (Lilly), Alexion Pharmaceuticals, Inc. (Alexion), and Boehringer Ingelheim International GmbH (BI). For more information, please visit www.dicerna.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements relating to the future growth of the Company. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and clinical programs and other risks identified under the heading "Risk Factors" included in our most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Dicerna™ and GalXCTM are trademarks of Dicerna Pharmaceuticals, Inc.